The adalimumab market is expected to witness a negative CAGR during the forecast period 2020-2026. Adalimumab is a biological drug sold by AbbVie Inc., under the brand name Humira for the treatment of various diseases including arthritis, Crohn's disease, ulcerative colitis, and others. The company was witnessing a significant growth until the patent of the drugs doesn’t expire in the US and Europe. In 2019, Humira generated revenue of $19.1 billion as compared to $19.9 billion in 2018.